Clinical trials: sponsored by Shanghai Minwei Biotechnology Co., Ltd
Healthy Volunteers
Phase 1 Clinical Study of MWN109 Injection in Healthy Chinese Volunteers
This is a randomized, double-blind, placebo-controlled, single- and multiple- dose-escalating Phase 1a study. The objective is to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and immunogenicity of MWN109…
- Trial name
- NCT07787624
- Testing
- MWN109
- Where
- China
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Shanghai Minwei Biotechnology Co., Ltd
Overweight , Obesity
Phase Ib Clinical Study of MWN109 Injection in Participants With Overweight or Obesity
This study is a randomized, double-blind, placebo-controlled, multiple-dose phase Ib clinical trial, aiming to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics and immunogenicity characteristics of MWN109…
- Trial name
- NCT07787728
- Testing
- MWN109 1, MWN109 2, MWN109 3
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Shanghai Minwei Biotechnology Co., Ltd
Healthy Volunteers, Obesity
Phase 1 Clinical Study of MWN117 Injection in Healthy Participants and Participants With Obesity
This study is a randomized, double-blind, placebo-controlled, single-dose, dose-escalation Phase 1 clinical trial to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of MWN117 injection in healthy and…
- Trial name
- NCT07824804
- Testing
- MWN117
- Where
- China
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Shanghai Minwei Biotechnology Co., Ltd
Type 2 Diabetes Mellitus (T2DM)
Phase 2 Clinical Study of MWN109 Tablets in Participants With Type 2 Diabetes Mellitus
This is a randomized, double-blind, placebo- and active-controlled, multicenter Phase II clinical trial designed to evaluate the efficacy, safety, and pharmacokinetic characteristics of MWN109 tablets in participants with type 2…
- Trial name
- NCT07801820
- Testing
- MWN109 1, MWN109 2, MWN109 3
- Where
- China
- Volunteers
- 240 people
- Sponsor
- Shanghai Minwei Biotechnology Co., Ltd
Essential Hypertension, Healthy Volunteers
Phase 1 Clinical Study of MWX401 Injection in Chinese Healthy Participants and Participants With Mild Hypertension
This is a single-center, randomized, double-blind, placebo-controlled, single ascending-dose phase 1 clinical study, aimed at evaluating the safety, tolerability, PK, PD and immunogenicity of single subcutaneous administration of…
- Trial name
- NCT07803835
- Testing
- MWX401 1, MWX401 2, MWX401 3
- Where
- China
- Volunteers
- 46 people, healthy volunteers welcome
- Sponsor
- Shanghai Minwei Biotechnology Co., Ltd
Overweight , Obesity, Type 2 Diabetes Mellitus (T2DM)
Phase 1 Clinical Study of MWN105 Injection in Participants With Overweight or Obesity
This study is a randomized, double-blind, placebo-controlled, multiple-dose, dose-escalation phase I clinical trial aiming to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and immunogenicity of MWN105…
- Conditions
- Overweight , Obesity, Type 2 Diabetes Mellitus (T2DM), MASH - Metabolic Dysfunction-Associated Steatohepatitis
- Trial name
- NCT07803809
- Testing
- MWN105 1, MWN105 2, MWN105 3
- Where
- China
- Volunteers
- 36 people
- Sponsor
- Shanghai Minwei Biotechnology Co., Ltd
Mixed Dyslipidemia
Phase 2 Clinical Study of MWX203 Injection Alone or in Combination With Inclisiran Sodium Injection in Patients With Mixed Dyslipidemia
This is a multicenter, randomized, blinded, placebo-controlled Phase 2 study designed to preliminarily evaluate the efficacy, safety, pharmacokinetic (PK), and immunogenicity profiles of MWX203 Injection alone or in combination…
- Trial name
- NCT07803822
- Testing
- MWX203, Inclisiran Sodium Injection
- Where
- China
- Volunteers
- 216 people
- Sponsor
- Shanghai Minwei Biotechnology Co., Ltd
Overweight , Obesity
Phase 2 Study of MWN109 Tablet for Weight-Loss Maintenance in Participants With Overweight or Obesity
This study adopted a randomized, open-label design, aiming to preliminarily explore the weight-loss maintenance effect of MWN109 tablets when administered continuously for 24 weeks in non-diabetic overweight or obese…
- Trial name
- NCT07804797
- Testing
- MWN109 1, MWN109 2
- Where
- China
- Volunteers
- 71 people
- Sponsor
- Shanghai Minwei Biotechnology Co., Ltd
Overweight , Obesity
Phase 2 Clinical Study of MWN105 Injection in Participants With Overweight or Obesity
This is a Phase 2, multicenter, randomized, double-blind, placebo-controlled study to evaluate the pharmacokinetic characteristics, efficacy, and safety of MWN105 Injection in non-diabetic participants with overweight or obesity.
- Trial name
- NCT07804810
- Testing
- MWN105 1, MWN105 2, MWN105 3
- Where
- China
- Volunteers
- 120 people
- Sponsor
- Shanghai Minwei Biotechnology Co., Ltd
Type 2 Diabetes Mellitus (T2DM), Overweight , Obesity
A Study to Evaluate Different Administration Conditions and the Food Effect of MWN109 Tablets in Chinese Participants
This is a randomized, open-label, multiple-dose study to evaluate the effects of different volumes of administration water, post-dose fasting duration, and high-fat diet on the pharmacokinetics of the 15 mg dose of MWN109 tablets…
- Trial name
- NCT07801326
- Testing
- MWN109 Tablets
- Where
- China
- Volunteers
- 162 people, healthy volunteers welcome
- Sponsor
- Shanghai Minwei Biotechnology Co., Ltd
Overweight , Obesity, Type 2 Diabetes Mellitus (T2DM)
Phase 1 Clinical Study of MWN105 Injection in Healthy Chinese Volunteers
This study is a randomized, double-blind, placebo-controlled, single-dose and multiple-dose, dose-escalation phase I clinical trial, aiming to evaluate the safety, tolerability, pharmacokinetic and pharmacodynamic…
- Conditions
- Overweight , Obesity, Type 2 Diabetes Mellitus (T2DM), MASH - Metabolic Dysfunction-Associated Steatohepatitis
- Trial name
- NCT07801313
- Testing
- MWN105
- Where
- China
- Volunteers
- 55 people, healthy volunteers welcome
- Sponsor
- Shanghai Minwei Biotechnology Co., Ltd
Healthy Volunteers
Phase 1 Clinical Study of MWX203 Injection in Healthy Subjects
This is a randomized, double-blind, placebo-controlled, single ascending dose Phase 1 study designed to evaluate the safety, tolerability, pharmacokinetic (PK), and pharmacodynamic (PD) profiles of MWX203 Injection in healthy…
- Trial name
- NCT07799025
- Testing
- MWX203 S1, MWX203 S2, MWX203 S3
- Where
- China
- Volunteers
- 54 people, healthy volunteers welcome
- Sponsor
- Shanghai Minwei Biotechnology Co., Ltd
Overweight , Obesity
Phase 2 Study to Evaluate the Efficacy and Safety of MWN109 Injection in Non-Diabetic Participants With Overweight
This study is a multicenter, randomized, double-blind, placebo-controlled phase II study conducted in China. It aims to evaluate the efficacy and safety of MWN109 injection in non-diabetic overweight or obese participants.
- Trial name
- NCT07791537
- Testing
- MWN109 1, MWN109 2, MWN109 3
- Where
- China
- Volunteers
- 125 people
- Sponsor
- Shanghai Minwei Biotechnology Co., Ltd
Overweight , Obesity
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 2 Study to Evaluate the Efficacy and Safety of MWN109 Injection in Non-Diabetic Participants With Overweight or Obesity
This study is a multicenter, randomized, double-blind, placebo-controlled phase II study conducted in China. It aims to evaluate the efficacy and safety of MWN109 injection in non-diabetic participants with overweight or obesity.
- Trial name
- NCT07791654
- Testing
- MWN109 1, MWN109 2, MWN109 3
- Where
- China
- Volunteers
- 120 people
- Sponsor
- Shanghai Minwei Biotechnology Co., Ltd
Overweight , Obesity
Phase 2 Study of MWN109 Tablet in Participants With Overweight or Obesity
This is a phase II, multicenter, randomized, double-blind, placebo-controlled clinical trial to preliminarily evaluate the efficacy, safety, and PK of MWN109 tablets administered orally once daily in non-diabetic participants…
- Trial name
- NCT07791524
- Testing
- MWN109 1, MWN109 2, MWN109 3
- Where
- China
- Volunteers
- 255 people
- Sponsor
- Shanghai Minwei Biotechnology Co., Ltd
Healthy Volunteers
Phase I Clinical Study of MWN109 Tablets in Healthy Chinese Participants
This is a randomized, double-blind, placebo-controlled, Phase 1 clinical study conducted in China to evaluate the safety, tolerability, pharmacokinetic (PK), and the effect of meal timing following single and multiple oral doses…
- Trial name
- NCT07787611
- Testing
- MWN109 tablet
- Where
- China
- Volunteers
- 98 people, healthy volunteers welcome
- Sponsor
- Shanghai Minwei Biotechnology Co., Ltd
Overweight , Obesity
Phase 1 Clinical Study of MWN110 Injection in Healthy Participants and Overweight or Obese Participants
This study is a multicenter, randomized, double-blind, placebo-controlled, single and multiple ascending-dose phase 1 clinical trial aimed at evaluating the safety, tolerability, PK, PD, and immunogenicity of MWN110 Injection in…
- Trial name
- NCT07779980
- Testing
- MWN110
- Where
- China
- Volunteers
- 103 people, healthy volunteers welcome
- Sponsor
- Shanghai Minwei Biotechnology Co., Ltd
Overweight , Obesity
Phase 3 Study of MWN109 Injection in Participants With Overweight or Obesity
This is a phase 3, multicenter, randomized, double-blind, placebo-controlled clinical trial to evaluate the efficacy and safety of MWN109 injection in non-diabetic participants with overweight or obesity.
- Trial name
- NCT07778693
- Testing
- MWN109 1, MWN109 2, MWN109 3
- Where
- China
- Volunteers
- 760 people
- Sponsor
- Shanghai Minwei Biotechnology Co., Ltd
Dyslipidemias
Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of MWX205
This study is being done to test a new injection called MWX205 in people with high cholesterol or fat levels in the blood (dyslipidemia). Researchers will check if a single dose of MWX205 is safe and how the body reacts to it.
- Trial name
- NCT07634510
- Testing
- MWX205
- Volunteers
- 37 people
- Sponsor
- Shanghai Minwei Biotechnology Co., Ltd
Overweight or Obesity
A Study to Evaluate MWN109 Tablets in Healthy Adult Participants
This is a Phase 1, randomized, double-blind, placebo-controlled, single-and-multiple ascending dose study in which the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and immunogenicity of orally administered…
- Trial name
- NCT06938269
- Testing
- MWN109 tablet
- Where
- 2 sites in Australia
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Shanghai Minwei Biotechnology Co., Ltd